Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Key Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment in the study. * Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer Stage IIIB, IIIC, or IV. * Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or central laboratory * Adequate cardiac function: * Left ventricular ejection fraction (LVEF) ≥ 50% as determined by ECHO or multi-gated acquisition (MUGA) scan and above the institutional lower limit of normal (LLN); * Triplicate average baseline QTcF value ≤ 450 ms. * Adequate bone marrow, organ function, and laboratory parameters: * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; * Hemoglobin ≥ 9 g/dL with or without transfusions; * Platelets ≥ 75 × 10⁹/L without transfusions; * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); in patients with liver metastases ≤ 5 × ULN; * Total bilirubin ≤ 1.5 × ULN; * Creatinine ≤ 1.5 × institutional ULN for age, or calculated creatinine clearance ≥ 70 mL/min/1.73 m² (following Schwartz formula). * Adequate performance status at Screening: * Patients \< 16 years old: Lansky Performance Scale score ≥ 80 * Patients 16 to 17 years old: Karnofsky Performance Scale score ≥ 80 Key Exclusion Criteria: Patients meeting any of the following criteria are not eligible for enrollment in the study. * Uveal or mucosal melanoma. * Brain metastases that are uncontrolled or symptomatic, require steroids, are potentially life-threatening or have required radiation within 28 days prior to starting study drug. * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO * Prior therapy with a BRAF inhibitor (e.g., dabrafenib, vemurafenib) and/or a MEK inhibitor (e.g., trametinib, cobimetinib). * Impaired cardiovascular function or clinically significant cardiovascular disease, including any of the following: * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) \< 6 months prior to screening, * Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality \< 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia. * Concurrent neuromuscular disorder associated with elevated creatine kinase (CK) * Uncontrolled arterial hypertension despite medical treatment * Presence of BRAFʷͭ or indeterminate melanoma in tumor tissue.